CureDuchenne Hosts Fourth Annual "Napa in Miami" Wine Tasting and Auction to Help Find a Cure for Duchenne Muscular Dystrophy

Premier Wine Series Will Bring Together Acclaimed Napa Valley Vintners Under One Roof in Miami to Benefit Global Nonprofit CureDuchenne

MIAMI, FL, March 12, 2025 – CureDuchenne, a global nonprofit committed to finding a cure for Duchenne muscular dystrophy, and Event Chair Susan Finazzo will host the fourth annual "Napa in Miami" Wine Tasting and Auction on April 5, 2025 at Mandarin Oriental, Miami. The premier wine event will bring a collection of Napa Valley vintners together under one roof to serve their finest vintages and offer their best wine experiences to Miami's top business leaders, influencers, entrepreneurs, philanthropists and wine connoisseurs.

Napa in Miami will feature a Grand Tasting, an exquisite dinner and spectacular auction lots – all to benefit CureDuchenne. Guests will enjoy handcrafted luxury wines made by the top producers of Napa Valley, one of the world's most desirable wine-growing regions in the world. These wines are only offered exclusively through the winery's limited allocation lists, making it a rare treat to taste so many of these wines together in one evening.

Since 2021, the Miami community has raised nearly $2.5 million to support CureDuchenne and its efforts to find and fund a cure for Duchenne muscular dystrophy. Duchenne muscular dystrophy is one of the most common and severe forms of muscular dystrophy and is mainly found in young boys. Most boys diagnosed with Duchenne lose the ability to walk by 12, and many lose their lives in their late 20s.

In 2020, Miami residents Chris and Susan Finazzo discovered that both of their sons, Chase, now age 10, and Dylan, now age 7, were in the earliest stages of Duchenne muscular dystrophy. They were devastated, but knew they must start advocating for the boys to get the best care and to help find a cure. After searching for answers, they found CureDuchenne, a nonprofit organization started by Debra and Paul Miller, whose own son's diagnosis inspired them to raise money to find a cure. Together, they manifested the idea of "Napa in Miami" to try and save their boys and the nearly 300,000 children and young adults living with the disease around the world. The Finazzo family has seen a glimmer of hope as both boys have participated in clinical trials for potential treatments, but their work is far from done as the disease still has no cure.

"We were devastated the day we found out both our sons were diagnosed with Duchenne. As a parent, you can't help but wonder if they'll have enough time to fall in love, to get married or ever get the joy of being a parent themselves," said Napa in Miami Chair Susan Finazzo. "But CureDuchenne has given us hope. CureDuchenne is on the forefront of the most promising research and with the help of fundraisers like Napa in Miami, we are that much closer to a cure."

"We are so grateful to the Miami community for their generous support through Napa in Miami. It's a one-of-a-kind event with the opportunity to enjoy rare and exclusive wines, but more importantly, attendees are helping us save a generation of children facing Duchenne muscular dystrophy," said CureDuchenne Founder and CEO Debra Miller. "We've made tremendous progress in research toward a cure, and every dollar makes a difference."

Event sponsors include Ace Endico and Universal Print Group. Sponsorships, tables and tickets are available. For more information, please visit www.thenapawineseries.com/napa-in-miami/.

About CureDuchenne

Over twenty years ago, CureDuchenne was created with one goal: to find and fund a cure for Duchenne muscular dystrophy, one of the most common and severe forms of muscular dystrophy. Today,

CureDuchenne is recognized as a global leader in research, patient care and innovation for improving and extending the lives of those with Duchenne. CureDuchenne's innovative venture philanthropy model has advanced transformative treatments for Duchenne muscular dystrophy, including 18 projects that advanced to human clinical trials and multiple projects to overcome the limitations of exon-skipping and gene therapy. In addition, CureDuchenne contributed early funding to the first FDA-approved Duchenne drug, pioneered the first and only Duchenne physical and occupational therapist certification program and created an innovative biobank and data registry, accelerating research toward a cure. For more information on how to help raise awareness and funds needed for research, please visit cureduchenne.org.

# # #